X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
REDUVO™ is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV). It is also used to treat weight loss and severe nausea in people living with HIV infection.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Gastroenterology Product Name: Reduvo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
Details:
REDUVO™ (dronabinol) is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV). It is also used to treat weight loss and severe nausea in people living with HIV infection.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Gastroenterology Product Name: Reduvo
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2022
Details:
ABO’s financing facility, to be used at the option of Tetra Bio-Pharma, allows the Company to finance the manufacturing costs of its QIXLEEF (cannabidiol) drug candidate.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: Qixleef
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alpha Blue Ocean
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Financing September 14, 2022
Details:
The company intends to use the net proceeds of the Financing to finance the manufacturing costs of its Qixleef (cannabidiol) drug candidate, to repay indebtedness and for working capital.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: Qixleef
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alpha Blue Ocean
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 08, 2022
Details:
ARDS-003 is a novel First in Human (FIH) drug product containing the active pharmaceutical agent, Onternabez, a potent and selective full agonist of the type 2 cannabinoid receptor (CB2R), an important immunomodulatory target.
Lead Product(s): Onternabez
Therapeutic Area: Infections and Infectious Diseases Product Name: ARDS-003
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
Under the multi-year agreement, Akanda will supply Tetra with high-quality, premium THC and CBD flower, and will provide regulatory, quality and pharmaceutical manufacturing services for the QIXLEEFTM clinical drug development and marketing authorization.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: Qixleef
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Akanda Corp
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 12, 2022
Details:
The partnership with Cannvalate and iNGEN, will encourage as it will allow the Company to further advance our QIXLEEF™ drug program, a promising alternative to opioids. Clinical data demonstrates that QIXLEEF™ has the potential to make a significant difference in patients.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: Qixleef
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cannvalate
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 17, 2022
Details:
Tetra has entered into a research agreement with Cannvalate for the performance of clinical trials of Tetra's drug candidates in Australia, including it's key programs: QIXLEEF™ and CAUMZ™.
Lead Product(s): Tetrahydrocannabinol,Cannabidiol
Therapeutic Area: Neurology Product Name: Qixleef
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cannvalate
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 05, 2022
Details:
The Company intends to use the proceeds of the Private Placement to fund its clinical trials and R&D activities for QIXLEEF and CAUMZ in collaboration with Cannvalate and iNGENū, in connection with the REBORN, PLENITUDE and CAUMZ clinical trials.
Lead Product(s): Tetrahydrocannabinol,Cannabidiol
Therapeutic Area: Neurology Product Name: Qixleef
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cannvalate
Deal Size: $5.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 05, 2022
Details:
Under the collaboration, Tetra will supply the synthetic cannabidiol drug products and placebo and in exchange will gain access to clinical data collected. The data will include safety, pharmacokinetic, and pharmacodynamic in humans exposed to Tetra's inhaled CBD product.
Lead Product(s): Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Montreal Hospital Research Centre
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
